
NDRA Stock Forecast & Price Target
NDRA Analyst Ratings
Bulls say
ENDRA Life Sciences Inc. is positioned for growth due to its innovative Thermo Acoustic Enhanced UltraSound (TAEUS) technology, which is designed to enhance diagnostic capabilities for liver diseases affecting over one billion people globally. The potential approval from the FDA within the next year serves as a key catalyst that could drive the stock higher, supported by a favorable net present value (NPV) analysis indicating significant upside potential. Additionally, TAEUS technology promises to provide more accurate and cost-effective diagnostics and monitoring of liver diseases compared to existing methods, highlighting an important market opportunity.
Bears say
ENDRA Life Sciences Inc reported a net loss of $1.6 million for the latest period, translating to an earnings per share (EPS) of $(2.10), which was worse than previous estimates of $(1.95). The company continues to face significant challenges, including balance sheet and liquidity risks, a lack of successful clinical trials for its product candidates, and difficulties related to regulatory approvals and commercialization efforts. Various external factors, including competition and changes in healthcare priorities, contribute to an overall negative outlook for the stock amidst these financial hurdles.
This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.
NDRA Analyst Forecast & Price Prediction
Start investing in NDRA
Order type
Buy in
Order amount
Est. shares
0 shares